Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04119596
Recruitment Status : Not yet recruiting
First Posted : October 8, 2019
Last Update Posted : October 11, 2019
Sponsor:
Information provided by (Responsible Party):
Atlas Biomed

Brief Summary:
A case-control study to identify microbiome and genetic differences between healthy subjects and patients with incident Parkinson's disease.

Condition or disease Intervention/treatment
Parkinson Disease Genetic Predisposition Diagnostic Test: 16S rRNA gene sequencing Genetic: DNA-microarray genotyping

Detailed Description:
Two groups of subjects - one including healthy individuals and the other - treatment-naive patients with incident Parkinson's disease - will fill in the food frequency questionnaire, SF-36 questionnaire, HADS questionnaire and the physical activity questionnaire. All subjects must have 0-3 points on Hoehn and Yahr scale and more than 22 points on MoCA scale. DNA microarray genotyping will be used to process the DNA samples of the participants. The data on the composition of the participants' gut microbiota will be obtained through 16S rRNA sequencing of their stool samples.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 200 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Estimated Study Start Date : February 1, 2020
Estimated Primary Completion Date : February 1, 2021
Estimated Study Completion Date : August 25, 2021

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
Diagnosed Parkinson's disease
Patients with incident Parkinson's disease
Diagnostic Test: 16S rRNA gene sequencing
Taking a stool sample for gut microbiome DNA sequencing

Genetic: DNA-microarray genotyping
Taking a saliva sample for genotyping

Control
Volunteers without diagnosed Parkinson's disease not meeting the exclusion criteria
Diagnostic Test: 16S rRNA gene sequencing
Taking a stool sample for gut microbiome DNA sequencing

Genetic: DNA-microarray genotyping
Taking a saliva sample for genotyping




Primary Outcome Measures :
  1. Gut microbiome composition of participants [ Time Frame: Baseline ]
    Bacterial relative abundance obtained via sequencing the DNA extracted from the stool sample

  2. Genotypes of participants [ Time Frame: Baseline ]
    High-throughput SNP profiling obtained via DNA-microarray genotyping of the DNA extracted from the saliva sample

  3. Hoehn, Yahr scale [ Time Frame: Baseline ]
    The Hoehn and Yahr scale defining five basic stages of PD progression (0-5)


Secondary Outcome Measures :
  1. Physical activity questionnaire [ Time Frame: Baseline ]
    Physical Activity Questionnaire - information on physical activity comprising 16 questions grouped in four domains: activity at work (1), travel to and from places (2), recreational activities (3), sedentary behaviour (4).

  2. Food frequency questionnaire [ Time Frame: 12 months before baseline ]
    Food frequency questionnaire assesses usual intake and portion size of more than 130 foods and beverages and more than 25 dietary supplements for the last 12 months. Responses are evaluated and analyzed to assess a dietary pattern for each group of subjects.

  3. Change in Stool consistency [ Time Frame: Baseline ]
    The Bristol stool scale is a diagnostic medical metric designed to classify the form of human faeces into seven categories

  4. Change in Stool frequency [ Time Frame: Baseline ]
    Change in the number of stool per week

  5. Change in Quality of Life: SF-36 questionnaire [ Time Frame: Baseline ]
    According to SF-36 questionnaire The Medical Outcomes Short-Form 36-Item Health Survey (SF-36) It is a self-administered questionnaire comprising 36-items measuring eight dimensions of general HRQOL: physical functioning (10 items), role limitation due to physical health problems (4 items), bodily pain (2 items), general health perceptions (5 items), vitality (4 items), social functioning (2 items), role limitations due to emotional problems (3 items), and general mental health (5 items). In addition to scores for individual dimensions, two summary scores assessing physical and mental dimensions of health and well-being can also be calculated: Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score, respectively

  6. Psychological distress questionnaire [ Time Frame: Baseline ]

    Hospital Anxiety and Depression Scale (HADS) The aim of this study is to measure patients anxiety and depression, using the HADS : Hospital Anxiety and Depression scale.

    Scores of the HADS scale can be defined as:

    By adding the points of the answers: 1, 3, 5, 7, 9, 11, 13: we obtain the "Total A" which corresponds to the measure of the anxiety, then:

    7 or less: absence of symptomatology; 8 to 10: doubtful symptomatology; 11 and above: certain symptomatology.

    By adding the points of the answers: 2, 4, 6, 8, 10, 12, 14: we obtain the "Total B" which corresponds to the measure of the depression, then:

    7 or less: absence of symptomatology; 8 to 10: doubtful symptomatology; 11 and above: certain symptomatology. The minimal score is 0 and the maximal total score is 42


  7. MOCA scale questionnaire [ Time Frame: Baseline ]

    The MoCA assesses several cognitive domains:

    The short-term memory recall task (5 points) involves two learning trials of five nouns and delayed recall after approximately five minutes.

    Visuospatial abilities are assessed using a clock-drawing task (3 points) and a three-dimensional cube copy (1 point).

    Multiple aspects of executive functions are assessed using an alternation task adapted from the trail-making B task (1 point), a phonemic fluency task (1 point), and a two-item verbal abstraction task (2 points).

    Attention, concentration, and working memory are evaluated using a sustained attention task (target detection using tapping; 1 point), a serial subtraction task (3 points), and digits forward and backward (1 point each).

    Language is assessed using a three-item confrontation naming task with low-familiarity animals (lion, camel, rhinoceros; 3 points), repetition of two syntactically complex sentences (2 points), and the aforementioned fluency task.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy volunteers and patients with incident Parkinson's disease from Russia
Criteria

Inclusion Criteria:

  • Men and women aged 45 years and over who have been diagnosed with Parkinson's disease
  • Subject signed informed consent

Exclusion Criteria:

  • Gastroenterological diseases such as ulcerative colitis, Crohn's disease, celiac disease, gallbladder diseases (calculous cholecystitis, cholangitis, etc.) that are not related to functional disorders, a liver diseases or pancreas in medical history
  • Exacerbations of chronic gastroenterological diseases
  • Mental illness
  • Oncology diseases
  • Mental disorders
  • Rheumatoid arthritis or other autoimmune diseases
  • Acute infectious diseases or exacerbation of any diseases
  • Recent (<3 months) administration of proton pump inhibitors, antimicrobial therapy or surgical intervention
  • Recent (<3 weeks) use of probiotics, antacids, nonsteroidal anti-inflammatory drugs, laxatives
  • Recent (<14 days) administration of laxatives (excluding prucaloprid)
  • Recent (< 3 months) surgical intervention
  • Pregnancy, planning to be pregnant or breast feeding at any point during the study or study enrollment
  • Current alcohol/drug abuse (more than 3 points for women and 4 for men according to AUDIT-C questionnaire and/or more than 7 points on the AUDIT questionnaire) or addiction therapy within 12 months prior to screening
  • Planned relocation from the home region during the study
  • Stroke in medical history
  • Any surgical intervention in the central nervous system
  • Morbid obesity, BMI> 35 kg / m2
  • A medical history of carriage or disease associated with a history of human immunodeficiency viruses, hepatitis B, C or Treponema pallidum
  • The patient's inability to understand the essence of the study and agree to participate in it. MoCA scores <22
  • 4-5 stage of the disease according to the Hen and Yara scale
  • Severe somatic pathologies or any factors that, in the opinion of the doctor, may prevent the patient from being included in the study
  • A medical history of serious head injuries
  • Rheumatoid arthritis
  • Tuberculosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04119596


Contacts
Layout table for location contacts
Contact: Natalia G Zhukova, MD, PhD +79138246202 znatali@yandex.ru
Contact: Vladimir A Romanov +79215797830 romanov@atlas.ru

Sponsors and Collaborators
Atlas Biomed

Layout table for additonal information
Responsible Party: Atlas Biomed
ClinicalTrials.gov Identifier: NCT04119596     History of Changes
Other Study ID Numbers: PSM
First Posted: October 8, 2019    Key Record Dates
Last Update Posted: October 11, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Atlas Biomed:
Gut Microbiota
Parkinson's disease
Genetics
Microbiome
FFQ
GPAQ
HADS
MOCA
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Disease Susceptibility
Genetic Predisposition to Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Disease Attributes
Pathologic Processes